Sign in
Taking peoplePhase 2

Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France8 sites in 1 countryChoose a country to see its sites
Status
Recruiting
Phase
Phase 2
People taking part
210 people, planned
Started
8 Apr 2024
Planned end
23 May 2026
Type of study
Interventional, 3 groups
Treatments tested
  • Placebo
  • Half dose CBD
  • Full dose CBD
Record updated
3 December 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (3)Hide the full registry criteria

Who can take part

  • Patients hospitalized for a scheduled alcohol inpatient cessation
  • Aged 18-75 years old; Meeting DSM 5 criteria for severe AUD; Willing to participate; Signing a written informed consent; Patients with current social insurance; For childbearing age, sexually active females: efficacious contraceptive method during treatment and up to seven days after treatment administration

Who cannot take part

  • • Patients already scheduled for long term residential care after acute alcohol inpatient detoxification, not able to maintain the outpatient follow up; Patients not willing to attend post-discharge visits whatever the reason; Any unstable medical condition at entry, such as delirium, acute hepatic failure, hypokalaemia, liver cirrhosis whatever the stage, acute or chronic severe renal failure or any acute psychiatric condition; Liver enzymes (ALT and/or AST) above 3 times the upper limit of normal and/or bilirubin above 2 times the upper limit of normal; Current medication or need for medication with treatments metabolized by CYP 2C19 or CYP3A4 or UGT enzymes and having strong inhibitor/inducer properties (see list above), and/or current medication or need for medications containing valproate and derivates; Any medical history of epileptic seizure; Patients with current or past history of cardiac arrhythmias, myocardial infarction and stroke; Any history of suicidal attempt in the past 5 years or a score ≥1 to the Suicidal Ideation Attributes Scale (SIDAS); To facilitate efficacy data interpretation, patients currently receiving or wanting to receive another approved pharmacological treatment aimed at alcohol abstinence maintenance (acamprosate, baclofene, disulfiram, nalmefene, naltrexone); Other major current DSM 5 severe substance use disorder (like opiates, cocaine, amphetamines, ...) except for tobacco, cannabis smoking and benzodiazepines use disorders; Pregnancy and breast feeding; Known hypersensitivity to the active substance or to any of the excipients (including PEG); Patients under guardianship; Patients in exclusion periods of other trials; Reversely, cannabis use or cannabis use disorders will not be an exclusion criteria

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Severe alcohol use disorder

This trial is currently available in France.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.

The 3 groups in the trial

  • PlaceboTreatment being tested

    add-on placebo (Echo Pharmaceutical, BV) for 11 days during their inpatient stay

  • Half-dose CBDTreatment being tested

    add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay

  • Full dose CBDTreatment being tested

    add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation in Patients With Severe Alcohol Use Disorder: A Phase II Trial
Criteria questions
Built from NCT05860699, who can take part
Record updated
3 December 2025